Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_assertion type Assertion NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_head.
- NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_assertion description "[Data from the Cancer and Leukemia Group B 8869/8541 study indicate enhanced dose responsiveness to doxorubicin (Adriamycin) in patients who overexpress the HER2 receptor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_provenance.
- NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_assertion evidence source_evidence_literature NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_provenance.
- NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_assertion SIO_000772 9563896 NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_provenance.
- NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_assertion wasDerivedFrom befree-20150227 NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_provenance.
- NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_assertion wasGeneratedBy ECO_0000203 NP378995.RA-xZRQGbJvWgSmLUqVECgqF57kVxvrp8GQBbgx3x4SAs130_provenance.